A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib

Inclusion Criteria

• •Clinical diagnosis of Axial Spondylarthritis (axSpA) according to the ASAS criteria.
• •Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score \>= 4 at Baseline.
• •Total back pain score \>= 4 at Baseline.
• •Inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to contraindication for NSAIDs as defined by the investigator.
• •Upadacitinib prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies.